source
- AbCellera, Silence and InduPro secure major funding rounds as AbCellera completes $200M share saleVancouver based biotech AbCellera announced a $200 million share offering after meeting its efficacy targets in a Phase 2 hot flashes trial. The capital raise follows the company achieving its pred…
- Sentynl inks up to $475M licensing deal to commercialize Mereo’s alvelestat for rare lung diseaseSentynl Therapeutics, a subsidiary of Zydus Lifesciences, signed an agreement to obtain exclusive U.S. rights to market alvelestat, Mereo BioPharma’s investigational therapy for alpha-1 antitrypsin…